文献速递肝肾功能剂量调整特殊人群用药

肾功能或肝损伤患者中抗癫痫药物的药代动力学、安全性与给药

Pharmacokinetics, Safety, and Dosing of Antiseizure Medications in Patients with Renal or Hepatic Impairment.
PubMed 文献 · Clin Pharmacokinet · 2026-08-21

本文综述了2000年后获批的十种新型抗癫痫药物在肾功能或肝损伤患者中的药代动力学与给药建议,整合关键开发项目数据及FDA与EMA至2025年的标签。结果显示药物对器官损伤的敏感性差异大,布瓦西坦、卢非酰胺和大麻二酚受肾功能下降影响小,而氯巴占和吡仑帕奈在严重器官功能障碍时需严格剂量上限或避免使用,司替戊醇因非线性动力学禁用于任何程度器官损伤。FDA与EMA标签存在差异。

要点

  • 布瓦西坦、卢非酰胺和大麻二酚对肾功能下降的敏感性较低。
  • 氯巴占和吡仑帕奈在严重器官功能障碍时需严格剂量上限或避免使用。
  • 司替戊醇因不可预测的非线性米氏动力学禁用于任何程度器官损伤。

核心结论

  • 新型抗癫痫药物在器官损伤中无统一类效应,处方须基于药物特异性处置特征和器官功能严重程度。

研究设计与样本

  • 叙述性综述,整合十种新型抗癫痫药物关键开发项目的药代动力学数据及FDA与EMA至2025年的监管标签。

主要发现

  • 布瓦西坦、卢非酰胺和大麻二酚对肾功能下降的敏感性较低。
  • 艾司利卡西平醋酸酯在轻至中度肝病中无需调整剂量。
  • 氯巴占和吡仑帕奈在严重器官功能障碍时需严格剂量上限或避免使用。
  • 司替戊醇因不可预测的非线性米氏动力学禁用于任何程度器官损伤。
  • FDA与EMA标签对所有十种药物均存在差异,包括吡仑帕奈和氯巴占的肝剂量上限、芬氟拉明的肾脏建议及艾司利卡西平醋酸酯在严重肾损伤中的指导。

临床怎么用

  • 处方时应根据具体药物的处置特征和器官功能严重程度个体化调整剂量。
  • 对高蛋白结合药物如吡仑帕奈和加奈索酮,考虑进行游离药物监测。
  • 需注意FDA与EMA标签在器官损伤给药建议上的差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ten newer antiseizure medications (ASMs) approved since 2000 and selected for this review (cenobamate, brivaracetam, eslicarbazepine acetate, lacosamide, perampanel, fenfluramine, ganaxolone, cannabidiol, stiripentol, and rufinamide) have broadened treatment options for drug-resistant epilepsy. However, concurrent renal or hepatic impairment alters drug disposition through diminished clearance, shifted protein binding equilibria, accumulation of active metabolites, and variable dialytic removal that standard dosing fails to accommodate. Despite the rising clinical overlap of epilepsy with chronic kidney and liver diseases, consolidated prescribing guidance for these agents in organ-impaired populations remains limited. This narrative review synthesizes pharmacokinetic data from pivotal development programs together with current regulatory labeling issued by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) through 2025 for all ten agents across graded severities of renal and hepatic impairment. Brivaracetam, rufinamide, and cannabidiol proved minimally susceptible to renal decline, whereas eslicarbazepine acetate required no hepatic dose adjustment in mild-to-moderate disease. Conversely, cenobamate and perampanel necessitate strict dose caps or avoidance in severe organ dysfunction, and stiripentol is precluded in any degree of organ impairment owing to unpredictable nonlinear Michaelis-Menten kinetics. Regulatory discrepancies between FDA and EMA labeling were identified for all ten agents, notably divergent hepatic dose caps for perampanel and cenobamate, conflicting renal recommendations for fenfluramine, and discordant guidance for eslicarbazepine acetate in severe renal impairment. These agents exhibit no uniform class effect in organ impairment; prescribing must be governed by agent-specific disposition profiles, organ-function severity, and free-drug monitoring for highly protein-bound agents like perampanel and ganaxolone.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Wu J, Li M, Wang S, et al. Pharmacokinetics, Safety, and Dosing of Antiseizure Medications in Patients with Renal or Hepatic Impairment. Clin Pharmacokinet. 2026. PMID: 42627450. doi:10.1007/s40262-026-01691-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。